Your browser doesn't support javascript.
loading
Cardiac and pulmonary findings in dysferlinopathy: A 3-year, longitudinal study.
Moore, Ursula; Fernandez-Torron, Roberto; Jacobs, Marni; Gordish-Dressman, Heather; Diaz-Manera, Jordi; James, Meredith K; Mayhew, Anna G; Harris, Elizabeth; Guglieri, Michela; Rufibach, Laura E; Feng, Jia; Blamire, Andrew M; Carlier, Pierre G; Spuler, Simone; Day, John W; Jones, Kristi J; Bharucha-Goebel, Diana X; Salort-Campana, Emmanuelle; Pestronk, Alan; Walter, Maggie C; Paradas, Carmen; Stojkovic, Tanya; Mori-Yoshimura, Madoka; Bravver, Elena; Pegoraro, Elena; Lowes, Linda Pax; Mendell, Jerry R; Bushby, Kate; Bourke, John; Straub, Volker.
Afiliación
  • Moore U; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Fernandez-Torron R; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Jacobs M; Neurology Department, Biodonostia Health Research Institute, Neuromuscular Area, Hospital Donostia, Basque Health Service, Donostia-San Sebastian, Spain.
  • Gordish-Dressman H; Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, District of Columbia, USA.
  • Diaz-Manera J; Pediatrics, Epidemiology and Biostatistics, George Washington University, Washington, District of Columbia, USA.
  • James MK; Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, District of Columbia, USA.
  • Mayhew AG; Pediatrics, Epidemiology and Biostatistics, George Washington University, Washington, District of Columbia, USA.
  • Harris E; Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain.
  • Guglieri M; Neuromuscular Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Rufibach LE; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Feng J; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Blamire AM; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Carlier PG; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Spuler S; The Jain Foundation, Seattle, Washington, USA.
  • Day JW; Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, District of Columbia, USA.
  • Jones KJ; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
  • Bharucha-Goebel DX; University Paris-Saclay, CEA, DRF, Service Hospitalier Frederic Joliot, Orsay, France.
  • Salort-Campana E; Charite Muscle Research Unit, Experimental and Clinical Research Center, a joint cooperation of the Charité Medical Faculty and the Max Delbrück Center for Molecular Medicine, Berlin, Germany.
  • Pestronk A; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
  • Walter MC; The Children's Hospital at Westmead, and The University of Sydney, Westmead, New South Wales, Australia.
  • Paradas C; Department of Neurology Children's National Health System, Washington, District of Columbia, USA.
  • Stojkovic T; National Institutes of Health (NINDS), Bethesda, Maryland, USA.
  • Mori-Yoshimura M; Service des maladies neuromusculaire et de la SLA, Hôpital de La Timone, Marseille, France.
  • Bravver E; Department of Neurology Washington University School of Medicine, St. Louis, Missouri, USA.
  • Pegoraro E; Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany.
  • Lowes LP; Neuromuscular Unit, Department of Neurology, Hospital U. Virgen del Rocío/Instituto de Biomedicina de Sevilla, Seville, Spain.
  • Mendell JR; Centre de référence des maladies neuromusculaires, Institut de Myologie, AP-HP, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.
  • Bushby K; Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Bourke J; Department of Neuroscience, University of Padova, Padua, Italy.
  • Straub V; The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
Muscle Nerve ; 65(5): 531-540, 2022 05.
Article en En | MEDLINE | ID: mdl-35179231
ABSTRACT
INTRODUCTION/

AIMS:

There is debate about whether and to what extent either respiratory or cardiac dysfunction occurs in patients with dysferlinopathy. This study aimed to establish definitively whether dysfunction in either system is part of the dysferlinopathy phenotype.

METHODS:

As part of the Jain Foundation's International Clinical Outcome Study (COS) for dysferlinopathy, objective measures of respiratory and cardiac function were collected twice, with a 3-y interval between tests, in 188 genetically confirmed patients aged 11-86 y (53% female). Measures included forced vital capacity (FVC), electrocardiogram (ECG), and echocardiogram (echo).

RESULTS:

Mean FVC was 90% predicted at baseline, decreasing to 88% at year 3. FVC was less than 80% predicted in 44 patients (24%) at baseline and 48 patients (30%) by year 3, including ambulant participants. ECGs showed P-wave abnormalities indicative of delayed trans-atrial conduction in 58% of patients at baseline, representing a risk for developing atrial flutter or fibrillation. The prevalence of impaired left ventricular function or hypertrophy was comparable to that in the general population.

DISCUSSION:

These results demonstrate clinically significant respiratory impairment and abnormal atrial conduction in some patients with dysferlinopathy. Therefore, we recommend that annual or biannual follow-up should include FVC measurement, enquiry about arrhythmia symptoms and peripheral pulse palpation to assess cardiac rhythm. However, periodic specialist cardiac review is probably not warranted unless prompted by symptoms or abnormal pulse findings.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Distrofia Muscular de Cinturas Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Muscle Nerve Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Distrofia Muscular de Cinturas Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Revista: Muscle Nerve Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido